KIFSB-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis

被引:17
作者
Cong, Xiao-Feng [1 ]
Yang, Lei [1 ]
Chen, Chen [1 ]
Liu, Ziling [1 ]
机构
[1] Jilin Univ, Hosp 1, Dept Oncol, Changchun 130021, Jilin, Peoples R China
关键词
pathological parameters; KIF5B-RET lung cancer; fusion gene; ADENOCARCINOMA PATIENTS; KIF5B-RET FUSIONS; TARGETED THERAPY; GROWTH-FACTOR; REARRANGEMENTS; MUTATIONS; EGFR; IDENTIFICATION; EPIDEMIOLOGY; RESISTANCE;
D O I
10.2147/OTT.S186361
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: The KIF5B-RET fusion gene is a novel oncogene that has been observed in a subset of lung cancers in recent years. However, the results of related epidemiological studies remain unclear. Thus, a meta-analysis was conducted to evaluate the correlation of KIF5B-RET expression based on RT-PCR detection with clinicopathological features and prognosis of lung cancer. Methods: The PubMed, Google Scholar, Wiley Online, SpringerLink and Chinese National Knowledge Infrastructure databases were searched to identify the eligible studies. The association of the occurrence of KIF5B-RET fusion gene in lung cancer with age, gender, smoking status, histology type, differentiation and TNM stage was analyzed. HR, overall survival (OS) and progression-free survival (PFS) were used to describe the prognosis of patients with lung cancer. The OR and 95% CI were calculated to assess the correlations. Random- and fixed-effects models were used to analyze the data. Results: A total of 13 studies, which included 8,859 lung cancer patients, were included in the study based on the inclusion criteria. A total of 121 patients with positive KIF5B-RET fusion gene status were detected, with a positive expression rate of 1.36%. KIF5B-RET fusion gene status was identified at significantly higher frequencies in female (OR=0.67, 95% CI=0.48-0.94) than male patients, and the same trend was found in young (<60 years) patients (OR=0.08, 95% CI=0.01-0.45) compared with old patients (>= 60 years). No differences were found in the TNM stage, histology, differentiation and smoking. Based on the prognosis, no difference was found between the status of the positive and negative KIF5B-RET fusion genes in OS and PFS of patients. Conclusion: The KIF5B-RET fusion gene occurred predominantly in young female patients with lung cancer. However, the relationship between the expression of the fusion gene and the prognosis of lung patients remains unclear.
引用
收藏
页码:4533 / 4542
页数:10
相关论文
共 35 条
[1]   The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2) [J].
Aisner, Dara L. ;
Sholl, Lynette M. ;
Berry, Lynne D. ;
Rossi, Michael R. ;
Chen, Heidi ;
Fujimoto, Junya ;
Moreira, Andre L. ;
Ramalingam, Suresh S. ;
Villaruz, Liza C. ;
Otterson, Gregory A. ;
Haura, Eric ;
Politi, Katerina ;
Glisson, Bonnie ;
Cetnar, Jeremy ;
Garon, Edward B. ;
Schiller, Joan ;
Waqar, Saiama N. ;
Sequist, Lecia V. ;
Brahmer, Julie ;
Shyr, Yu ;
Kugler, Kelly ;
Wistuba, Ignacio I. ;
Johnson, Bruce E. ;
Minna, John D. ;
Kris, Mark G. ;
Bunn, Paul A. ;
Kwiatkowski, David J. .
CLINICAL CANCER RESEARCH, 2018, 24 (05) :1038-1047
[2]  
Akcay S, 2016, J LUNG CANC DIAGN TR, V1, P105, DOI [10.4172/jlcdt.1000105, DOI 10.4172/JLCDT.1000105]
[3]   EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation [J].
Antonicelli, Alberto ;
Cafarotti, Stefano ;
Indini, Alice ;
Galli, Alessio ;
Russo, Andrea ;
Cesario, Alfredo ;
Lococo, Filippo Maria ;
Russo, Patrizia ;
Mainini, Alberto Franco ;
Bonifati, Luca Giuseppe ;
Nosotti, Mario ;
Santambrogio, Luigi ;
Margaritora, Stefano ;
Granone, Pierluigi Maria ;
Dutly, Andre Emanuel .
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (03) :320-330
[4]   KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung [J].
Borrelli, Nicla ;
Giannini, Riccardo ;
Proietti, Agnese ;
Ali, Greta ;
Pelliccioni, Serena ;
Niccoli, Cristina ;
Lucchi, Marco ;
Melfi, Franca ;
Mussi, Alfredo ;
Basolo, Fulvio ;
Fontanini, Gabriella .
LUNG CANCER, 2013, 81 (03) :377-381
[5]   KIF5B-RET fusions in Chinese patients with nonsmall cell lung cancer [J].
Cai, Weijing ;
Su, Chunxia ;
Li, Xuefei ;
Fan, Lihong ;
Zheng, Limou ;
Fei, Ke ;
Zhou, Caicun .
CANCER, 2013, 119 (08) :1486-1494
[6]   Epidemiology of lung cancer in China [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zeng, Hongmei ;
Zhang, Siwei .
THORACIC CANCER, 2015, 6 (02) :209-215
[7]   Lung Cancer: Epidemiology, Etiology, and Prevention [J].
Dela Cruz, Charles S. ;
Tanoue, Lynn T. ;
Matthay, Richard A. .
CLINICS IN CHEST MEDICINE, 2011, 32 (04) :605-+
[8]   Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].
Engelman, Jeffrey A. ;
Jaenne, Pasi A. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :2895-2899
[9]   Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer [J].
Hart, Christopher D. ;
De Boer, Richard H. .
ONCOTARGETS AND THERAPY, 2013, 6 :1-7
[10]   Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma [J].
Huang, Qingling ;
Schneeberger, Valentina E. ;
Luetteke, Noreen ;
Jin, Chengliu ;
Afzal, Roha ;
Budzevich, Mikalai M. ;
Makanji, Rikesh J. ;
Martinez, Gary V. ;
Shen, Tao ;
Zhao, Lichao ;
Fung, Kar-Ming ;
Haura, Eric B. ;
Coppola, Domenico ;
Wu, Jie .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) :2521-2529